Log in
Enquire now
‌

US Patent 10590092 Process for the manufacture of isavuconazole or ravuconazole

Patent 10590092 was granted and assigned to Basilea Pharmaceutica on March, 2020 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors
Patent abstract

The invention relates to a process for the manufacture of diastereomerically and enantiomerically enriched triazole compounds isavuconazole and ravuconazole, comprising a Reformatsky reaction between a ketone and a 2-halozincpropionate ester, followed by a resolution step, preferably an enzymatic resolution with an esterase enzyme.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10590092 Process for the manufacture of isavuconazole or ravuconazole

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo